Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Modalis Therapeutics

モダリス

4883 · TSE · Pharmaceutical · 1 article

Financials Consolidated

Ordinary profit−¥2.15bnConsolidated · FY12/25

Net profit−¥2.15bnConsolidated · FY12/25

Performance over time

Ordinary profit
−¥1.23bnFY12/21
−¥2.00bnFY12/22
−¥2.35bnFY12/23
−¥1.30bnFY12/24
−¥2.15bnFY12/25
Net profit (attributable)
−¥739mFY12/21
−¥2.70bnFY12/22
−¥2.39bnFY12/23
−¥1.32bnFY12/24
−¥2.15bnFY12/25
Op. cash flow
−¥747mFY12/21
−¥1.90bnFY12/22
−¥2.25bnFY12/23
−¥1.43bnFY12/24
−¥2.12bnFY12/25

People & pay

Employees, whole group17 peopleFY12/25

Employees, parent company (non-consolidated)3 peopleFY12/25

Average salary¥6.14mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSTotal assetsNet assetsOp. cash flow
FY12/25—−¥2.15bn−¥2,153m−¥27.86¥2.96bn¥2.79bn−¥2,118m
FY12/24—−¥1.30bn−¥1,318m−¥28.57¥3.69bn¥3.55bn−¥1,432m
FY12/23—−¥2.35bn−¥2,392m−¥77.24¥2.03bn¥1.38bn−¥2,254m
FY12/22¥40.50m+3581.8% year on year−¥2.00bn−¥2,703m−¥92.85¥3.13bn¥2.94bn−¥1,896m
FY12/21¥1.10m−¥1.23bn−¥739m−¥25.70¥6.07bn¥5.55bn−¥747m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XSHO · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4883

Tokyo Brief coverage

All articles loaded · 1 shown

5% holders

Latest disclosed holders and exits below 5%.

1 holder · data through

No stored data for this selection.

Exits below 5%

Exits below 5%
HolderStakeChangePurposeFiling
Evo Fund4.89% own · 4.89% group of 2−1.82 ppPure investment
Read full ownership purposePure investment. No specific circumstances are assumed, but Filer No. 1 may, depending on the circumstances from time to time, provide appropriate advice to the issuer.
Machine translated
Original (Japanese)純投資。特定の状況は想定されていないが、第1提出者は発行者に対しその時々の状況に応じて適切な助言を行う場合がある。
Filed  — filing S100ZJ2B